NCT07034742 - Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2028

Conditions

Gastric Adenocarcinoma

Interventions

DRUG

Intraperitoneal chemotherapy PLUS systemic chemotherapy

Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)

Trial Locations (1)

Unknown

RECRUITING

Chaoyang District, Panjiayuan Nanli NO.17, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER